A5002938685- Inflammatory Bowel Disease
- Microscopic Colitis
- Eosinophilic Esophagitis
- Surgical Simulation and Training
- Medical Device Sterilization and Disinfection
- Gastroesophageal reflux and treatments
- Advances in Oncology and Radiotherapy
- Autoimmune and Inflammatory Disorders
- Diagnosis and treatment of tuberculosis
- Liver Disease and Transplantation
- Health Systems, Economic Evaluations, Quality of Life
- Vasculitis and related conditions
- Ocular Diseases and Behçet’s Syndrome
- Otitis Media and Relapsing Polychondritis
- Hidradenitis Suppurativa and Treatments
- Diverticular Disease and Complications
- Acute Lymphoblastic Leukemia research
- Colorectal Cancer Treatments and Studies
- Organ Transplantation Techniques and Outcomes
- Clinical Nutrition and Gastroenterology
- Immunodeficiency and Autoimmune Disorders
- Helicobacter pylori-related gastroenterology studies
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Inflammatory Myopathies and Dermatomyositis
- Nutrition, Genetics, and Disease
Joint Base San Antonio
2021-2024
Brooke Army Medical Center
2017-2024
Wilford Hall Ambulatory Surgical Center
2022-2024
San Antonio Uniformed Services Health Education Consortium
2016-2020
University of Rochester Medical Center
2017
INTRODUCTION: A significant proportion of patients with acute severe ulcerative colitis (ASUC) require colectomy. METHODS: Patients ASUC treated upadacitinib and intravenous corticosteroids at 5 hospitals are presented. The primary outcome was 90-day colectomy rate. Secondary outcomes included frequency steroid-free clinical remission, adverse events, all-cause readmissions. RESULTS: Of the 25 upadacitinib, 6 (24%) underwent colectomy, 15 (83%) 18 available data who did not undergo...
Pivotal trials have shown that ustekinumab is effective in ulcerative colitis (UC). However, the population included these do not represent cohort of patients treated real world. In this study, we aimed to describe effectiveness and safety a clinical with UC.
Introduction: Per the American College of Gastroenterology (ACG) Guidelines, refractory GERD is managed by first optimizing proton pump inhibitor (PPI) therapy. If typical symptoms persist, further work-up should include upper endoscopy to exclude disease processes like eosinophilic and erosive esophagitis. negative, or if patient has atypical already evaluated other subspecialties, recommendation pursue pH/impedance monitoring quantify reflux establish symptom correlation direct future...
Introduction: Crohn’s disease (CD) is characterized by transmural inflammation and ongoing inflammatory activity, which over time results in the accumulation of bowel damage, may lead to complications such as strictures, fistulas/fissures, abscesses, well disability. Optimally controlling early course CD, during ‘window opportunity,’ be best way change course. Recent evidence clinical practice guidelines suggest that biologic therapy preferred treating moderate severe CD. Early use...
Introduction: Behcet's disease (BD) is a multisystem inflammatory condition often characterized by gastrointestinal manifestations. The prevalence of highest in Asian and Eurasian populations, but rarely encountered among individuals African descent. ileocecal region most commonly affected BD, though ulcers maybe found throughout the colon. Although therapy with immunomodulators anti-tumor necrosis factor (TNF)-alpha have shown efficacy cases intestinal many patients become refractory to...
Article Title: Long-term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCU
Article Title: Preoperative Risk Factors for Adverse Events in Adults Undergoing Bowel Resection Inflammatory Disease: 15-Year Assessment of the American College Surgeons National Surgical Quality Improvement Program.
Behcet’s disease (BD) is a multisystem mucocutaneous inflammatory condition characterized by recurrent genital and oral ulcers, ocular inflammation, can involve the gastrointestinal tract. Treatment involves usage of immunosuppressive agents to control with glucocorticoids utilized for treatment flares. Tumor necrosis factor inhibitors are frequently used as well. We present case 40 years old African American female presenting intestinal BD that was refractory adalimumab therapy. In...
Dasatinib is an oral tyrosine kinase inhibitor approved for usage in Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome positive (Ph+) Acute Lymphocytic Leukemia. Elevations of aminotransferases bilirubin have been reported patients taking dasatinib with without baseline hepatic dysfunction. However, grade 3-4 dysfunction occurs 0- < 1% all treated dasatinib. This case describes a 42 year old female history Ph+CML on treatment 2 months presenting jaundice. The patient had...
Introduction: The American College of Gastroenterology recommends that patients with gastroesophageal reflux disease (GERD) undergo esophageal pH and impedance for symptoms persisting following an 8 week trial proton pump inhibitor (PPI) therapy. Research suggests early referral is cost effective in evaluating PPI refractory GERD. Methods: A retrospective chart review was performed on all underwent pH/impedance studies from December 2010 to June 2015. DeMeester score, total acid non-acid...
INTRODUCTION: Hemostatic powders (e.g. TC-325) are FDA-approved for the treatment of non-variceal gastrointestinal bleeding. TC-325 is an inorganic powder that becomes coherent on contact with moisture in tract. It acts as a barrier hemostasis to provide scaffold clot formation and enhance platelet aggregation. We present case patient massive upper bleeding hemostatic used temporizing emergent prior variceal band ligation. CASE DESCRIPTION/METHODS: Our 58 year old man history alcohol abuse...
INTRODUCTION: Autoimmune Enteropathy (AIE) is a rare condition without established treatment guidelines. Typical symptoms include intractable diarrhea unresponsive to dietary changes, malabsorption, and weight loss. Common pathological findings villous atrophy, crypt apoptotic bodies, lack of intraepithelial lymphocytes, loss goblet Paneth cells. Anti-enterocyte anti-goblet cell antibodies are found in 60-100% 40%, respectively. Corticosteroids first line followed by immunosuppressive...
Article Title: Irritable bowel syndrome and long-term risk of cancer: a prospective cohort study among 0.5 million adults in UK Biobank.
Article Title: Efficacy and Safety of Infliximab Retreatment in Crohn's Disease: A Multicenter, Prospective, Observational Cohort (REGAIN) Study.
Introduction: Ulcerative colitis (UC) is a heterogeneous and unpredicTable disease with the potential for worsening over time should be regarded as progressive disease. More recent evidence clinical practice guidelines suggest that biologic therapy preferred initial in treating moderate to severe UC. However, despite these guidelines, little research has been done determine optimal timing initiation of therapy. Data on impact early intervention UC are limited, whether more intensive...